



Substitute for form 1449A/PTO

Complete if Known

# **FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/527,411
Filing Date	November 10, 2005 (§ 371 Date)
First Named Inventor	SHONE, Charles Clifford
Art Unit	1645
Examiner Name	Archie, Nina
Attorney Docket Number	1581.0130005/RWE

Sheet 1 of 2

## **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US10	2003/0180289 A1	09/25/2003	Foster <i>et al.</i>	
	US11	2005/0013831 A1	01/20/2005	Foster <i>et al.</i>	
	US12	2005/0244435 A1	11/03/2005	Shone <i>et al.</i>	
	US13	2005/0255093 A1	11/17/2005	Shone <i>et al.</i>	
	US14	2006/0110409 A1	05/25/2006	Shone <i>et al.</i>	
	US15	7,052,702 B1	05/30/2006	Duggan <i>et al.</i>	
	US16	2006/0121056 A1	06/08/2006	Chaddock <i>et al.</i>	
	US17	2007/0010447 A1	01/11/2007	Quinn <i>et al.</i>	
	US18	7,193,066 B1	03/20/2007	Chaddock <i>et al.</i>	
	US19	7,192,596 B2	03/20/2007	Shone <i>et al.</i>	
	US20	2007/0071764 A1	03/29/2007	Sullivan <i>et al.</i>	
	US21	7,208,466 B1	04/24/2007	Foster <i>et al.</i>	
	US22	2007/0148694 A1	06/28/2007	Shone <i>et al.</i>	
	US23	2007/0184048 A1	08/09/2007	Foster <i>et al.</i>	
	US24	2007/0184070 A1	08/09/2007	Shone <i>et al.</i>	
	US25	2007/0248626 A1	10/25/2007	Shone <i>et al.</i>	
	US26	2008/0032930 A1	02/07/2008	Steward <i>et al.</i>	
	US27	2008/0032931 A1	02/07/2008	Steward <i>et al.</i>	
	US28	2008/0032928 A1	02/07/2008	Quinn <i>et al.</i>	
	US29	2008/0038274 A1	02/14/2008	Foster <i>et al.</i>	
	US30	2008/0064092 A1	03/13/2008	Foster <i>et al.</i>	
	US31	2008/0070278 A1	03/20/2008	North <i>et al.</i>	
	US32	7,368,532 B2	05/06/2008	Shone <i>et al.</i>	
	US33	2008/0152667 A1	06/26/2008	Quinn <i>et al.</i>	
	US34	2008/0161543 A1	07/03/2008	Steward <i>et al.</i>	
	US35	2008/0187960 A1	08/07/2008	Foster <i>et al.</i>	
	US36	7,413,742 B2	08/19/2008	Donovan	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
	FP4	WO 2006/026780 A1	03/09/2006	Allergan, Inc.	
	FP5	WO 2006/059093 A2	06/08/2006	Health Protection Agency; Allergan, Inc.	
	FP6	WO 2006/059105 A2	06/08/2006	Health Protection Agency	
	FP7	WO 2007/138336 A2	12/06/2007	Syntaxin Limited; Allergan, Inc.	
	FP8	WO 2007/138339 A2	12/06/2007	Syntaxin Limited; Allergan, Inc.	
	FP9	WO 2008/008805 A2	01/17/2008	Allergan, Inc.	

Examiner Signature	/Nina Archie/	Date Considered	08/27/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES ARE CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/527,411
Filing Date	November 10, 2005 (§ 371 Date)
First Named Inventor	SHONE, Charles Clifford
Art Unit	1645
Examiner Name	Archie, Nina
Attorney Docket Number	1581.0130005/RWE

[illegible][illegible]

990597 1.DOC

Examiner Signature	/Nina Archie/	Date Considered	/Nina Archie/
--------------------	---------------	-----------------	---------------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send To: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./



Equivalent of Form PTO/SB/08b (2-09)

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/527,411
				Filing Date	November 10, 2005 (§ 371 Date)
				First Named Inventor	SHONE, Clifford Charles
				Art Unit	1645
				Examiner Name	Archie, Nina
Sheet	1	of	3	Attorney Docket Number	1581.0130005/RWE

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	NPL4	Atassi, M.Z., "Basic Immunological Aspects of Botulinum Toxin Therapy," <i>Movement Disorders</i> 19: S68-S84, Movement Disorder Society (2004)			
	NPL5	Blaustein, R.O., <i>et al.</i> , "The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers," <i>F.E.B.S. Letters</i> 226:115-120, Elsevier Science Publishers B.V. (1987)			
	NPL6	Bowie J.U., <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> 247:1306-1310, American Association for the Advancement of Science (1990)			
	NPL7	Brüggemann, H., <i>et al.</i> , "The genome sequence of <i>Clostridium tetani</i> , the causative agent of tetanus disease," <i>PNAS</i> 100:1316-1321, National Academy of Sciences (2003)			
	NPL8	Brunger, A.T., <i>et al.</i> , "Botulinum Neurotoxin Heavy Chain Belt as an Intramolecular Chaperone for the Light Chain," <i>PLoS Pathogens</i> 3:1191-1194 (2007)			
	NPL9	Byrne, M.P., <i>et al.</i> , "Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from <i>Pichia pastoris</i> as a Recombinant Vaccine Candidate," <i>Infection and Immunity</i> 66:4817-4822, American Society for Microbiology (1998)			
	NPL10	Byrne, M.P., <i>et al.</i> , "Development of vaccines for prevention of botulism," <i>Biochimie</i> 82:955-966, Elsevier SAS (2000)			
	NPL11	Creighton, T.E., Proteins, pages 314-315, W.H. Freeman Company (1984)			
	NPL12	Creighton, T.E., Protein Structure: A Practical Approach, pages 184-186, IRL Press (1989)			
	NPL13	Eisel, U., <i>et al.</i> , "Tetanus toxin: primary structure, expression in <i>E. coli</i> , and homology with botulinum toxins," <i>The EMBO Journal</i> 5:2495-2502, IRL Press Limited (1986)			
	NPL14	Goonetilleke, A., <i>et al.</i> , "Clostridial Neurotoxins," <i>J Neurol Neurosurg Psychiatry</i> 75:iii35-iii39, BMJ Journals (2004)			
	NPL15	Hill, K.K., <i>et al.</i> , "Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains," <i>Journal of Bacteriology</i> 189:818-832, American Society of Microbiology (2007)			

Examiner Signature	/Nina Archie/	Date Considered	08/27/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/527,411
				Filing Date	November 10, 2005 (§ 371 Date)
				First Named Inventor	SHONE, Clifford Charles
				Art Unit	1645
				Examiner Name	Archie, Nina
Sheet	2	of	3	Attorney Docket Number	1581.0130005/RWE

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL16	Kumar, V., <i>et al.</i> , "Amino Acid Variations at a Single Residue in an Autoimmune Peptide Profoundly Affect its Properties: T-Cell Activation, Major Histocompatibility Complex Binding, and Ability to Block Experimental Allergic Encephalomyelitis," <i>PNAS</i> 87:1337-1341, National Academy of Sciences (1990)	
	NPL17	Nosoh, Y., Protein Stability and Stabilization Through Protein Engineering, pages 197-217, Prentice Hall (1991)	
	NPL18	Abstract of Park, J-B., <i>et al.</i> , "Progress toward development of an inhalation vaccine against botulinum toxin," <i>Expert Review of Vaccines</i> 3:477-487, Expert Reviews Ltd. (2004)	
	NPL19	Sebaihia, M., <i>et al.</i> , "Genome sequence of a proteolytic (Group I) <i>Clostridium botulinum</i> strain Hall A and comparative analysis of the clostridial genomes," <i>Genome Research</i> 17:1082-1092, Cold Spring Harbor Laboratory Press (2007)	
	NPL20	Shone, C.C., <i>et al.</i> , "A 50-kDa fragment from the NH <sub>2</sub> -terminus of the heavy subunit of <i>Clostridium botulinum</i> type A neurotoxin forms channels in lipid vesicles," <i>Eur. J. Biochem</i> 167:175-180, F.E.B.S. (1987)	
	NPL21	Willems, A., <i>et al.</i> , "Sequence of the gene coding for the neurotoxin of <i>Clostridium botulinum</i> type A associated with infant botulism: comparison with other clostridial neurotoxins," <i>Res. Microbiol.</i> 144:547-556, Elsevier (1993)	
	NPL22	Office Action mailed March 21, 2008 in U.S. Patent Appl. No. 11/077,550 to Shone, C.C., <i>et al.</i>	
	NPL23	Amendment and Reply Under 37 C.F.R. § 1.111 filed July 21, 2008 in U.S. Patent Appl. No. 11/077,550 to Shone, C.C., <i>et al.</i>	
	NPL24	Office Action mailed October 27, 2008 in U.S. Patent Appl. No. 11/077,550 to Shone, C.C., <i>et al.</i>	
	NPL25	Reply Under 37 C.F.R. § 1.116 filed February 19, 2009 in U.S. Patent Appl. No. 11/077,550 to Shone, C.C., <i>et al.</i>	

Examiner Signature	/Nina Archie/	Date Considered	08/27/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/527,411
				Filing Date	November 10, 2005 (§ 371 Date)
				First Named Inventor	SHONE, Clifford Charles
				Art Unit	1645
				Examiner Name	Archie, Nina
Sheet	3	of	3	Attorney Docket Number	1581.0130005/RWE

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL26	Office Action mailed March 30, 2009 in U.S. Patent Appl. No. 11/077,550 to Shone, C.C., <i>et al.</i>	
	NPL27	Office Action mailed April 6, 2009 in U.S. Patent Appl. No. 11/644,010 to Shone, C.C., <i>et al.</i>	
	NPL28	Copy of co-pending U.S. Application No. 12/399,542, inventors Shone, C.C., <i>et al.</i> , filed March 6, 2009 (NOT PUBLISHED)	
	NPL29	Copy of co-pending U.S. Application No. 12/369,341, inventors Shone, C.C., <i>et al.</i> , filed February 11, 2009 (NOT PUBLISHED)	
	NPL30	Copy of co-pending U.S. Application No. 12/174,896, inventors Shone, C.C., <i>et al.</i> , filed July 17, 2008 (NOT PUBLISHED)	

990652\_1.DOC

Examiner Signature	/Nina Archie/	Date Considered	08/27/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./